Oncology

Protein degrader
#Cancer research #Immunoassay #Oncology #PROTAC #Protein degradation #Webinar

Webinar: The application of targeted protein degradation in oncology research

Register now to secure your place at a new free-to-attend webinar on 23 September entitled ‘PROTAC-Mediated CDK2 degradation in oncology: Immunoassay tools for therapeutic discovery’, hosted by DDW and supported by Revvity. Audrey Johnson, a scientist at Beantown Biotech, explores the innovative application of targeted… Read More

Webinar date:
Supported by Revvity
#News

Lung cancer
#BioNTech #Bristol Myers Squibb #Lung cancer #Oncology #Phase II trial

Bispecific antibody trial shows encouraging antitumour activity

BioNTech and Bristol Myers Squibb have revealed global interim Phase II data for their PD-L1xVEGF-A bispecific antibody pumitamig in patients with extensive-stage small cell lung cancer (ES-SCLC) which shows encouraging antitumour activity.  The data for pumitamig plus chemotherapy showed a 76.3% confirmed objective response rate (cORR), 100%… Read More

#Cancer Research #News

Cancer cells
#Cancer research #Immunoassay #Oncology #PROTAC #Protein degradation #Webinar

Webinar: The significance of CDK2 in oncology research

Register now to secure your place at a new free-to-attend webinar on 23 September entitled ‘PROTAC-Mediated CDK2 degradation in oncology: Immunoassay tools for therapeutic discovery’, hosted by DDW and supported by Revvity. Audrey Johnson, a scientist at Beantown Biotech, explores the innovative application of targeted… Read More

Webinar date:
Supported by Revvity
#News

London skyline
#CRISPR #CRISPR screening #Drug discovery #Genomics #Oncology

Registration open for DDW Symposium in London 

Registration is now open for the DDW Turning Science into Business Symposium. It will take place at the Francis Crick Institute in London on 4 November 2025.   Register here for tickets.  The half day event boasts a stellar line up… Read More

#News

Cancer research lab
#Cancer research #Drug development #Drug discovery #Oncology

UK immigration system is a barrier to cancer research, says CRUK 

A new report from Cancer Research UK (CRUK) indicates that the UK immigration system is having a detrimental effect on research in the UK.  CRUK’s institutes are led by and made up of a combination of UK and international researchers, but now it says that the UK… Read More

#News

Cancer cells
#Cancer #Cancer biology #Oncology #Tumour microenvironment (TME)

Microenvironment switches cancer cells to a drug-resistant state  

A new study has revealed that the mechanical environment surrounding a tumour can cause cancer cells to change their behaviour, triggering a switch from rapid growth to a more invasive, drug-resistant state.  Traditionally, epigenetic changes have been thought to arise from internal cellular processes, such as histone… Read More

#News

Protein degradation
#Cancer research #Immunoassay #Oncology #PROTAC #Protein degradation #Webinar

Webinar explores PROTAC-Mediated CDK2 degradation in oncology

Register now to secure your place at a new free-to-attend webinar on 23 September entitled ‘PROTAC-Mediated CDK2 degradation in oncology: Immunoassay tools for therapeutic discovery’, hosted by DDW and supported by Revvity. Audrey Johnson, a scientist at Beantown Biotech, explores the innovative application of targeted… Read More

Webinar date:
Supported by Revvity
#News

Vaccine research
#Cancer drug targets #Oncology #Proteomics #The Institute of Cancer Research

Redox proteomics reveals potential target for cancer therapies

Researchers have discovered that a subtle chemical change to protein p21 acts as a master regulator of cell division – a finding that could influence future cancer therapies.  The study was launched at the Biotechnology Center (BIOTEC) of TUD Dresden University of Technology in Germany and later… Read More

#Cancer Research #Editor's Choice #News

#Cancer research #Immunoassay #Oncology #PROTAC #Protein degradation #Webinar

New webinar: Immunoassay tools for therapeutic discovery

Register now to secure your place at a new free-to-attend webinar on 23 September entitled ‘PROTAC-Mediated CDK2 degradation in oncology: Immunoassay tools for therapeutic discovery’, hosted by DDW and supported by Revvity. Audrey Johnson, a scientist at Beantown Biotech, explores the innovative application of targeted… Read More

Webinar date:
Supported by Revvity
#News

#Cancer research #Immunoassay #Oncology #PROTAC #Protein degradation

PROTAC-Mediated CDK2 degradation in oncology: Immunoassay tools for therapeutic discovery

In this webinar, hosted by DDW and supported by Revvity, Audrey Johnson, a scientist at Beantown Biotech, explores the innovative application of targeted protein degradation (TPD) in oncology research, with a specific focus on CDK2 degradation for potential cancer treatments. Johnson is joined during the Q&A by Rachel Mendes, Senior… Read More

Webinar date:
Supported by Revvity
#Webinars

Doctor showing a model of the prostate
#Bayer #Health Canada #Oncology #Prostate cancer

Health Canada extends approval of Bayer’s darolutamide

Health Canada has granted marketing authorisation for Bayer’s oral androgen receptor inhibitor (ARi) Nubeqa (darolutamide) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).   This authorisation is based on results from the Phase III ARANOTE trial, which showed that darolutamide plus ADT reduced the risk of radiological progression… Read More

#News #Regulatory

Colon cancer
#Colorectal cancer #Larkspur Biosciences #Oncology #Preclinical development #Solid tumours

First degrader of lipid kinase PIP4K2C shows promise in colon cancer

Larkspur Biosciences has announced the discovery of LRK-4189, a first-in-class degrader of the lipid kinase PIP4K2C for the treatment of microsatellite stable (MSS) colorectal cancer (CRC) and other solid tumours.   The announcement was made at ACS Fall 2025, a meeting of the American Chemical Society in Washington,… Read More

#Cancer Research #News

Long Covid concept
#Covid-19 #Genetics / genomics #Long Covid #Oncology #Spatial biology

Enhancing cancer and long Covid research

Genomic and spatial technologies are helping to bring greater insights into cancer and diseases such as long Covid, writes Jack DiGiovanna, Chief Science Officer at Velsera. Emerging genomic and spatial technologies are transforming research on complex diseases like cancer and long Covid. These advancements offer unprecedented precision in diagnostics and… Read More

#Cancer Research #Exclusive Content

Hepatitis virus
#Oncology #Oncolytic virus #Personalised medicine #The Institute of Cancer Research #Virology

Combining viruses with targeted cancer drugs boosts response

Two studies have uncovered how combining a reovirus with targeted cancer drugs can dramatically boost immune responses and tumour destruction – offering a promising route to more effective, personalised cancer therapies.  Researchers at The Institute of Cancer Research, London, have shown that this combination involving virotherapy can… Read More

#Cancer Research #Editor's Choice #News